KK College of Pharmacy, Gerugambakam, Chennai, India.

Akhlaghi, Seyed Hamid

doi:10.18502/ijdo.v15i3.13739

Volume 15, Issue 3 (10-2023) IJDO 2023, 15(3): 181-189 | Back to browse issues page

‎ 10.18502/ijdo.v15i3.13739

‎ 20.1001.1.20086792.2023.15.3.6.2

Mendeley

Zotero

RefWorks

Akhlaghi S H. KK College of Pharmacy, Gerugambakam, Chennai, India.. IJDO 2023; 15 (3) :181-189
URL: http://ijdo.ssu.ac.ir/article-1-819-en.html

KK College of Pharmacy, Gerugambakam, Chennai, India.

Seyed Hamid Akhlaghi ^*

KK College of Pharmacy, Gerugambakam, Chennai, India.

Abstract: (325 Views)

Objective: This study aimed to conduct a systematic review about diabetes mellitus and COVID-19 severity, management, and mortality.
Materials and Methods: Thirteen studies were included in this review, comprising a total of 1155 COVID-19 patients with diabetes mellitus as a significant comorbidity. Data regarding patient demographics and the prevalence of comorbidities, including smoking, hypertension, cardiovascular disease, chronic kidney disease, and chronic liver disease, were collected.
Results: Among COVID-19 patients with diabetes mellitus, the majority were male (57.1%) compared to females (42.9%). The prevalence of comorbidities in COVID-19 are varied, with smokers accounting for 1-12.6%, hypertension ranging from 8-41.6%, diabetes mellitus ranging from 7.4-70.8%, cardiovascular disease ranging from 1.6-23.0%, chronic kidney disease ranging from 0.7-2.9%, and chronic liver disease ranging from 0.5-4.6%. In comparison to COVID-19 patients without diabetes, a higher proportion of patients with diabetes mellitus were admitted to the intensive care unit (36.8%). Among COVID-19 patients with diabetes mellitus, the survival rate was significantly higher at 62.2% compared to a lower rate of 13.4% observed among non-survivors with diabetes mellitus.
Conclusion: This systematic review emphasizes the significance of diabetes mellitus as a comorbidity in COVID-19 patients, increasing the risk of ICU admission. These findings emphasize the importance of identifying and effectively managing diabetes mellitus as a comorbidity in COVID-19 patients to enhance overall outcomes.

Keywords: COVID-19, Diabetes mellitus, Diabetes complications, SARS-CoV-2

Full-Text [PDF 649 kb] (152 Downloads)

Type of Study: Research | Subject: Special
Received: 2023/04/22 | Accepted: 2023/07/28 | Published: 2023/09/30

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-6. [DOI:10.1016/S0140-6736(20)30566-3]

2. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes care. 2020;43(7):1382-91. [DOI:10.2337/dc20-0598]

3. Guo T, Shen Q, Ouyang X, Guo W, Li J, He W, et al. Clinical findings in diabetes mellitus patients with COVID-19. Journal of diabetes research. 2021;2021:7830136. [DOI:10.1155/2021/7830136]

4. Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19. Diabetes, obesity and metabolism. 2020;22(10):1897-906. [DOI:10.1111/dom.14099]

5. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The lancet respiratory medicine. 2020;8(5):475-81. [DOI:10.1016/S2213-2600(20)30079-5]

6. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine. 2020;180(7):934-43. [DOI:10.1001/jamainternmed.2020.0994]

7. Chen T, Wu DI, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. British Medical Journal. 2020;368:m1091. [DOI:10.1136/bmj.m1091]

8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20. [DOI:10.1056/NEJMoa2002032]

9. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of translational medicine. 2020;18(1):1-2. [DOI:10.1186/s12967-020-02374-0]

10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. The Journal of the American Medical Association. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585]

11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5]